Multiomic Market Forecast by Instruments, Consumables, and Others from 2024 to 2034
Increasing Integration of Big Data Analytics and Artificial Intelligence in Multiomic Data Interpretation is Driving the Global Expansion of the Multiomic Market
The multiomic market is expected to be valued at US$ 3.9 billion in 2024 and rise to US$ 15.3 billion by 2034. The market is predicted to grow at a CAGR of 14.8% during the forecast period. The rising prevalence of chronic disorders and complex health conditions necessitates holistic approach in spurring the market.
Key Market Drivers
With the objective of omics sciences to identify and quantify biological molecules for the upliftment of biological beings, there is a huge rise in the multiomics market. Some factors are mentioned below.
High demand for multiomic solutions in pharmaceuticals and biotech sectors for insights into drug discovery and development.
Clinical diagnostics is witnessing a surge in multiomic technology adoption for accuracy in disease diagnosis and personalized treatments.
Multiomic applications are boosting agri-genomics, facilitating enhanced crop breeding programs and agricultural productivity.
Environmental monitoring embraces multiomic aspects to understand ecosystem dynamics and address pollution challenges.
Nutrigenomics is leveraging multiomic techniques to develop tailored dietary interventions, resulting in steady growth in the nutrition and wellness sectors.
Bioinformatics services catering to multiomic data analysis and interpretation are accelerating growth in the computational biology segment.
Startups and niche players specializing in multiomic platforms are diversifying the market landscape and contributing to its expansion.
Attributes
Key Statistics
Multiomic Market Value (2024)
US$ 3.9 billion
Anticipated Market Value (2034)
US$ 15.3 billion
Estimated Growth (2024 to 2034)
14.8% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Diverse Applications of Multiomics Drive its Profitability in Various Fields
Despite the healthy growth of multiomics market with heavy demand in omics sectors, several factors are slowing down the market.
Clinical Laboratories are increasingly adopting multiomic analysis, boosting their sales and increasing the accuracy of their diagnoses.
Agricultural research institutions and companies are adopting multiomic technologies to meet the uprising need for advanced crop breeding programs and sustainable agriculture practices.
Governments and industries are turning to multiomic approaches in environmental monitoring and remediation, seeking more effective solutions for ecosystem management challenges.
The need for personalized dietary recommendations based on genetic and metabolic profiles is fueling the demand for multiomics in the nutrition and wellness sector.
The computational biology market is seeing increased sales of multiomic data analysis tools, as researchers require advanced algorithms for interpreting complex biological datasets.
Academic research institutions are hiking demand for specialized equipment and reagents as they adopt multiomic technologies.
Demand for integrated multiomic solutions that offer seamless data integration and analysis capabilities has increased in the biotechnology and life sciences sectors.
Challenges Impeding Growth in the Multiomic Market
High costs of equipment, reagents, and data analysis tools, especially in resource-limited settings have pushed the adoption of multiomic technology.
Data interpretation and analysis complexity require specialized infrastructure and expertise, hindering the implementation of multiomic approaches.
Limited standardization and interoperability of multiomic platforms and data formats may impede the implementation of multiomic approaches.
Regulatory uncertainties surrounding the usage of multiomic technologies in clinical settings may hinder market growth due to stringent approval processes.
Insufficient awareness and understanding of multiomic approaches among healthcare professionals, researchers, and policymakers may hold back the market.
Limited scalability of multiomic technologies may restrict their applicability in large-scale studies or industrial applications, impacting market penetration.
Find your sweet spots for generating winning opportunities in this market.
Comparative View of Adjacent Industries
The section focuses on two markets that could pose stiff competition with the multiomic market. These are the proteomics market and the genome editing market.
The table below outlines the current market valuations and growth rates of these markets. The report also includes a discussion on the growth drivers and critical challenges faced by each of these markets.
Multiomic Market:
Attributes
Multiomic Market
CAGR (2024 to 2034)
14.8%
Market Value (2034)
US$ 15.3 billion
Growth Factor
Increasing demand for single-cell multiomics and overall omics technology advancements for healthcare betterment
High cost of medicines, equipment and scarcity of research scholars
Genome Editing Market:
Attributes
Genome Editing Market
CAGR (2024 to 2034)
15.7%
Market Value (2034)
US$ 26.5 billion
Growth Factor
New editing technologies and increased research and development activities
Key Challenges
Therapeutic applications of genome editing, particularly in vivo delivery
Category-wise Insights
Multiomics Services Provide Specialised Expertise and Analysis
Multiomics service providers ensure quality assurance and validation and the segment is expected to expand at a 14.6% CAGR through 2034.
Attributes
Details
Top Component
Services
CAGR (2024 to 2034)
14.6%
Multiomics service providers offer specialized expertise and consultation to interpret complex data and provide tailored solutions to clients.
Service providers offer customized multiomic analysis packages that cater to diverse research objectives and industry requirements, enhancing their significance in the global market.
Multiomics service providers ensure quality assurance and validation throughout the analysis process, instilling confidence in clients regarding the accuracy and reliability of results.
Key companies are providing continuous support and training to clients, aids in efficient utilization of multiomic technologies, and ensures ongoing collaboration and satisfaction.
Precise Cellular Insights and Diverse Applications Paved the way for the Upliftment of Single-Cell Multiomics Technology
Based on the type, the single-cell multiomics segment is projected to grow at a 14.4% CAGR from 2024 to 2034.
Attributes
Details
Top Type
Single-Cell Multi-Omics
CAGR (2024 to 2034)
14.4%
Unparalleled resolution and precision, which allow analysis of cellular heterogeneity at the individual cell level, are offered by single-cell multiomics technologies.
Single-cell multiomics technologies provide valuable insights into intricate cellular dynamics and regulatory networks, helping in understanding disease mechanisms, drug responses, and developmental processes.
Single-cell multiomics approaches are enabling personalized medicine initiatives by profiling individual cells within heterogeneous tissues, thus facilitating the identification of biomarkers, therapeutic targets, and patient-specific treatment strategies.
Expanding research landscape across various disciplines, such as oncology, immunology, neuroscience, and developmental biology, demands high-resolution multiomic analyses at the single-cell level to unravel complex biological processes and disease pathways
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Country-wise Insights
The section analyzes the global multiomic market by country, including the United Kingdom, the United States, China, South Korea, and Japan. The table presents the CAGR for each country, indicating the expected market growth through 2034.
Countries
CAGR through 2034
South Korea
17.0%
Japan
16.4%
United Kingdom
16.0%
China
15.5%
United States
15.1%
Extensive Network of Medical Institutions and Universal Coverage in South Korea Boost Healthcare Sector
With growing demand for personalized medicine and advancements in precision healthcare, South Korea is well-positioned to capitalize on the opportunities presented by the expanding multiomics market with a projected CAGR of 17.0% from 2024 to 2034.
Strong research infrastructure, government support, and highly skilled workforce pave the way in South Korea’s global multiomics market expansion. Institutions such as the Korean Institute of Science and Technology (KIST), Seoul National University (SNU), and Korea Advanced Institute of Science and Technology (KAIST) have emerged as leaders in multiomics research due to their high-tech facilities and collaborations with major industry partners.
Government support through initiatives like the Bio-Vision 2016 strategy and the Bio-Cluster Development Project has further heightened the growth of the biotech sector in South Korea
Japan's Emphasis on Patient-Centeredness Positions it as a Significant Player in Omics Research
With a robust infrastructure, skilled workforce, and a culture of innovation, Japan is well-positioned to continue its expansion in the multiomics market, with a CAGR of 16.4% through 2034.
Cutting-edge technologies and meticulous research methodologies, and has fostered numerous distinguished research labs and institutions dedicated to multiomics in Japan. Collaborative efforts between academia, industry, and government have propelled Japan's multiomics sector forward, developing advanced analytical platforms such as mass spectrometry and next-generation sequencing technologies.
Japan's multiomics landscape is characterized by a vibrant ecosystem of startups, biotech companies, and research consortia actively contributing to the commercialization and adoption of multiomics technologies.
Key players like Takara Bio, Illumina, and Shimadzu Corporation have leveraged Japan's research capabilities to develop high-throughput platforms for genomic and proteomic analysis, catering to diverse drug discovery, diagnostics, and agricultural biotechnology applications.
Multi-Stakeholder Research System in the United Kingdom Aids the growth of the Multiomic Market
The United Kingdom is upheading the multiomics market with innovative research, advanced bioinformatics tools, and exceptional infrastructure. With a CAGR of 16.0% projected through 2034, it is maintaining a steady pace of growth.
The United Kingdom has made remarkable strides in multiomics research, and its collaboration with biotechnology companies and academic institutions has led to groundbreaking discoveries and commercialization of innovative technologies.
World-class research facilities and supportive policies for the life sciences sector have attracted top talent and investment in the United Kingdom, facilitating the translation of research findings into market-ready products and services. The United Kingdom is driving advancements in personalized medicine, drug discovery, and precision agriculture, enhancing its growth in the global market.
Rapid Growth and Significant Government Investments in China to Accelerate Market Growth
Investments in research foundations and infrastructure to support multiomics research and development, establishing world-class institutions, and collaborating with renowned international partners, China is emerging as a key player in the market. The market in China is expected to rise at a CAGR of 15.5% from 2024 to 2034.
China has a vast population with diverse genetic backgrounds, providing an enormous pool of research subjects for multiomics studies. This has led to the expansion of advanced healthcare solutions tailored for individual genetic profiles.
China has also invested significantly in research foundations and infrastructure to support multiomics research and development, establishing world-class institutions and collaborating with renowned international partners. Ongoing strategic investments, population demand, and a collaborative approach position China as a key player in the global market.
The Multiomic Market in the United States is Evolving With Reputed Biotech Companies
The presence of key players in the biotech and pharma sector fuels investment and fosters partnerships, accelerating the adoption of multiomics solutions in the United States market. Thus, ongoing advancement and research fuel market growth, with an expected CAGR of 15.1%, which is expected to persist until 2034.
The rising demand for advanced healthcare solutions to tackle chronic disorders is an emerging forerunner for the United States market. With a significant burden of chronic diseases such as diabetes, cardiovascular disorders, and cancer, the multiomics approach integrating genomics, proteomics, and metabolomics offers a comprehensive understanding of disease mechanisms and personalized treatment options.
The country's robust ecosystem of research laboratories, medical centers, and biotech companies supports innovation and collaboration in multiomics research and development, leading to the discovery of novel biomarkers and the development of advanced analytical tools.
Competitive Landscape
The field of omics research is marked by several renowned laboratories, which are known for their groundbreaking contributions. The Broad Institute, the Wellcome Sanger Institute, and the Max Planck Institute for Molecular Genetics are some of the most esteemed institutions in the field, particularly for their pioneering work in genomics, transcriptomics, proteomics, and other related areas.
In addition, Illumina, Thermo Fisher Scientific, and 10x Genomics are pivotal players in the multiomics market are also in row for expansion through their innovative approaches.
These companies are consistently developing advanced sequencing technologies, integrated platforms, and comprehensive analysis software, facilitating the seamless integration of multiomic data. Thus strategic collaborations with other industry leaders such as Qiagen, Agilent Technologies, and BGI Genomics are further enhancing the accessibility, scalability, and reliability of multiomics solutions, which can help market scale upwards.
Recent Developments
On February 24, 2024, Vizzhy CEO Dr. Vishnuvardhan unveiled the world's first Multiomics Lab in Bangalore, marking a breakthrough in healthcare innovation. The initiative was announced during the soft launch event of the Vizzhy Multiomics platform, revolutionizing the approach to understanding and treating metabolic disorders.
On October 10, 2023, CENTOGENE expanded its Multiomic diagnostic portfolio with the launch of a newly-introduced Transcriptomic offering. The announcement was made in Cambridge, Mass., Rostock, Germany, and Berlin, signifying a significant advancement in life science.
On August 29, 2023, BioSkryb Genomics partnered with Research Instruments Pte Ltd to bring industry-leading Single-Cell Technologies to Singapore and Southeast Asia. The strategic distribution agreement expanded access to BioSkryb's best-in-class single-cell multiomics portfolio throughout the region.
Key Companies in the Market
Becton
Dickinson and Company
Thermo Fisher Scientific Inc.
Illumina, Inc
Danaher
PerkinElmer, Inc.
Bruker Corporation
Qiagen N.V.
Agilent Technologies, Inc.
BGI Group
Becton, Dickinson, and Company
Shimadzu Corporation
Key Coverage in the Multiomic Market Report
Detailed Study in Applications of Multi-Omics Analysis in Human Diseases
Assessment of the Multi-omics data integration tools and methods
Multiomics Analysis Software Demand Analysis
Market Analysis on Choosing Catheter Materials- Flexible and tough
Insights into the Difference Between Single Omics and Multi-Omics
Call for Machine Learning Methods for Multi-Omics Data Integration
Market Segmentation
By Component:
Instruments
Consumables
Software
Services
By Multiomic Type:
Single-Cell Multi-Omics
Bulk Multi-Omics
By Platform:
Genomics
Transcriptomics
Proteomics
Metabolomics
Integrated Omics Platforms
By Application:
Oncology
Cell Biology
Neurology
Immunology
Other Applications
By Region:
North America
Latin America
Asia Pacific
Middle East and Africa (MEA)
Europe
Frequently Asked Questions
What is the Multiomic Market Worth in 2024?
The multiomic market is projected to be valued at US$ 3.9 billion in 2024.
What is the Sales Forecast for the Multiomics through 2034?
The multiomic market is expected to reach a valuation of US$ 15.3 billion by 2034.
At What Rate is the Multiomic Market Expected to Grow?
The multiomic market is expected to grow at a CAGR of 14.8% from 2024 to 2034.
What was the Valuation of the Multiomics Market in 2019?
The valuation of the multiomic market was 1.7 billion in 2019.
Who are the Key Manufacturers in the Market?
Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Illumina, Inc., and Danaher are among the major companies actively contributing to the growth of the global multiomic market.
What is the Top Type of Multiomic Research?
Single-cell multiomics is the top type, which is anticipated to grow at a 14.4% CAGR through 2034.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Component
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Component, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Component, 2024 to 2034
5.3.1. Instruments
5.3.2. Consumables
5.3.3. Software
5.3.4. Services
5.4. Y-o-Y Growth Trend Analysis By Component, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Component, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2024 to 2034
6.3.1. Single-Cell Multiomic
6.3.2. Bulk Multiomic
6.4. Y-o-Y Growth Trend Analysis By Type, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Type, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Platform
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Platform, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Platform, 2024 to 2034
7.3.1. Genomics
7.3.2. Transcriptomics
7.3.3. Proteomics
7.3.4. Metabolomics
7.3.5. Integrated Omics Platforms
7.4. Y-o-Y Growth Trend Analysis By Platform, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Platform, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Application, 2019 to 2023
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2024 to 2034
8.3.1. Oncology
8.3.2. Cell Biology
8.3.3. Neurology
8.3.4. Immunology
8.3.5. Other Applications
8.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023
8.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-User
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2019 to 2023
9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2024 to 2034
9.3.1. Academic and Research Organizations
9.3.2. Pharmaceutical & Biotechnology Companies
9.3.3. Hospital and Diagnostic Laboratories
9.3.4. Other End-Users
9.4. Y-o-Y Growth Trend Analysis By End-User, 2019 to 2023
9.5. Absolute $ Opportunity Analysis By End-User, 2024 to 2034
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
10.1. Introduction
10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
10.3.1. North America
10.3.2. Latin America
10.3.3. Western Europe
10.3.4. Eastern Europe
10.3.5. South Asia and Pacific
10.3.6. East Asia
10.3.7. Middle East and Africa
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. USA
11.2.1.2. Canada
11.2.2. By Component
11.2.3. By Type
11.2.4. By Platform
11.2.5. By Application
11.2.6. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Component
11.3.3. By Type
11.3.4. By Platform
11.3.5. By Application
11.3.6. By End-User
11.4. Key Takeaways
12. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Brazil
12.2.1.2. Mexico
12.2.1.3. Rest of Latin America
12.2.2. By Component
12.2.3. By Type
12.2.4. By Platform
12.2.5. By Application
12.2.6. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Component
12.3.3. By Type
12.3.4. By Platform
12.3.5. By Application
12.3.6. By End-User
12.4. Key Takeaways
13. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. Germany
13.2.1.2. UK
13.2.1.3. France
13.2.1.4. Spain
13.2.1.5. Italy
13.2.1.6. Rest of Western Europe
13.2.2. By Component
13.2.3. By Type
13.2.4. By Platform
13.2.5. By Application
13.2.6. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Component
13.3.3. By Type
13.3.4. By Platform
13.3.5. By Application
13.3.6. By End-User
13.4. Key Takeaways
14. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. Poland
14.2.1.2. Russia
14.2.1.3. Czech Republic
14.2.1.4. Romania
14.2.1.5. Rest of Eastern Europe
14.2.2. By Component
14.2.3. By Type
14.2.4. By Platform
14.2.5. By Application
14.2.6. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Component
14.3.3. By Type
14.3.4. By Platform
14.3.5. By Application
14.3.6. By End-User
14.4. Key Takeaways
15. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. India
15.2.1.2. Bangladesh
15.2.1.3. Australia
15.2.1.4. New Zealand
15.2.1.5. Rest of South Asia and Pacific
15.2.2. By Component
15.2.3. By Type
15.2.4. By Platform
15.2.5. By Application
15.2.6. By End-User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Component
15.3.3. By Type
15.3.4. By Platform
15.3.5. By Application
15.3.6. By End-User
15.4. Key Takeaways
16. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
16.2.1. By Country
16.2.1.1. China
16.2.1.2. Japan
16.2.1.3. South Korea
16.2.2. By Component
16.2.3. By Type
16.2.4. By Platform
16.2.5. By Application
16.2.6. By End-User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Component
16.3.3. By Type
16.3.4. By Platform
16.3.5. By Application
16.3.6. By End-User
16.4. Key Takeaways
17. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
17.2.1. By Country
17.2.1.1. GCC Countries
17.2.1.2. South Africa
17.2.1.3. Israel
17.2.1.4. Rest of MEA
17.2.2. By Component
17.2.3. By Type
17.2.4. By Platform
17.2.5. By Application
17.2.6. By End-User
17.3. Market Attractiveness Analysis
17.3.1. By Country
17.3.2. By Component
17.3.3. By Type
17.3.4. By Platform
17.3.5. By Application
17.3.6. By End-User
17.4. Key Takeaways
18. Key Countries Market Analysis
18.1. USA
18.1.1. Market Share Analysis, 2023
18.1.1.1. By Component
18.1.1.2. By Type
18.1.1.3. By Platform
18.1.1.4. By Application
18.1.1.5. By End-User
18.2. Canada
18.2.1. Market Share Analysis, 2023
18.2.1.1. By Component
18.2.1.2. By Type
18.2.1.3. By Platform
18.2.1.4. By Application
18.2.1.5. By End-User
18.3. Brazil
18.3.1. Market Share Analysis, 2023
18.3.1.1. By Component
18.3.1.2. By Type
18.3.1.3. By Platform
18.3.1.4. By Application
18.3.1.5. By End-User
18.4. Mexico
18.4.1. Market Share Analysis, 2023
18.4.1.1. By Component
18.4.1.2. By Type
18.4.1.3. By Platform
18.4.1.4. By Application
18.4.1.5. By End-User
18.5. Germany
18.5.1. Market Share Analysis, 2023
18.5.1.1. By Component
18.5.1.2. By Type
18.5.1.3. By Platform
18.5.1.4. By Application
18.5.1.5. By End-User
18.6. UK
18.6.1. Market Share Analysis, 2023
18.6.1.1. By Component
18.6.1.2. By Type
18.6.1.3. By Platform
18.6.1.4. By Application
18.6.1.5. By End-User
18.7. France
18.7.1. Market Share Analysis, 2023
18.7.1.1. By Component
18.7.1.2. By Type
18.7.1.3. By Platform
18.7.1.4. By Application
18.7.1.5. By End-User
18.8. Spain
18.8.1. Market Share Analysis, 2023
18.8.1.1. By Component
18.8.1.2. By Type
18.8.1.3. By Platform
18.8.1.4. By Application
18.8.1.5. By End-User
18.9. Italy
18.9.1. Market Share Analysis, 2023
18.9.1.1. By Component
18.9.1.2. By Type
18.9.1.3. By Platform
18.9.1.4. By Application
18.9.1.5. By End-User
18.10. Poland
18.10.1. Market Share Analysis, 2023
18.10.1.1. By Component
18.10.1.2. By Type
18.10.1.3. By Platform
18.10.1.4. By Application
18.10.1.5. By End-User
18.11. Russia
18.11.1. Market Share Analysis, 2023
18.11.1.1. By Component
18.11.1.2. By Type
18.11.1.3. By Platform
18.11.1.4. By Application
18.11.1.5. By End-User
18.12. Czech Republic
18.12.1. Market Share Analysis, 2023
18.12.1.1. By Component
18.12.1.2. By Type
18.12.1.3. By Platform
18.12.1.4. By Application
18.12.1.5. By End-User
18.13. Romania
18.13.1. Market Share Analysis, 2023
18.13.1.1. By Component
18.13.1.2. By Type
18.13.1.3. By Platform
18.13.1.4. By Application
18.13.1.5. By End-User
18.14. India
18.14.1. Market Share Analysis, 2023
18.14.1.1. By Component
18.14.1.2. By Type
18.14.1.3. By Platform
18.14.1.4. By Application
18.14.1.5. By End-User
18.15. Bangladesh
18.15.1. Market Share Analysis, 2023
18.15.1.1. By Component
18.15.1.2. By Type
18.15.1.3. By Platform
18.15.1.4. By Application
18.15.1.5. By End-User
18.16. Australia
18.16.1. Market Share Analysis, 2023
18.16.1.1. By Component
18.16.1.2. By Type
18.16.1.3. By Platform
18.16.1.4. By Application
18.16.1.5. By End-User
18.17. New Zealand
18.17.1. Market Share Analysis, 2023
18.17.1.1. By Component
18.17.1.2. By Type
18.17.1.3. By Platform
18.17.1.4. By Application
18.17.1.5. By End-User
18.18. China
18.18.1. Market Share Analysis, 2023
18.18.1.1. By Component
18.18.1.2. By Type
18.18.1.3. By Platform
18.18.1.4. By Application
18.18.1.5. By End-User
18.19. Japan
18.19.1. Market Share Analysis, 2023
18.19.1.1. By Component
18.19.1.2. By Type
18.19.1.3. By Platform
18.19.1.4. By Application
18.19.1.5. By End-User
18.20. South Korea
18.20.1. Market Share Analysis, 2023
18.20.1.1. By Component
18.20.1.2. By Type
18.20.1.3. By Platform
18.20.1.4. By Application
18.20.1.5. By End-User
18.21. GCC Countries
18.21.1. Market Share Analysis, 2023
18.21.1.1. By Component
18.21.1.2. By Type
18.21.1.3. By Platform
18.21.1.4. By Application
18.21.1.5. By End-User
18.22. South Africa
18.22.1. Market Share Analysis, 2023
18.22.1.1. By Component
18.22.1.2. By Type
18.22.1.3. By Platform
18.22.1.4. By Application
18.22.1.5. By End-User
18.23. Israel
18.23.1. Market Share Analysis, 2023
18.23.1.1. By Component
18.23.1.2. By Type
18.23.1.3. By Platform
18.23.1.4. By Application
18.23.1.5. By End-User
19. Market Structure Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Market Share Analysis of Top Players
19.3.1. By Regional
19.3.2. By Component
19.3.3. By Type
19.3.4. By Platform
19.3.5. By Application
19.3.6. By End-User
20. Competition Analysis
20.1. Competition Deep Dive
20.1.1. Becton, Dickinson and Company
20.1.1.1. Overview
20.1.1.2. Product Portfolio
20.1.1.3. Profitability by Market Segments
20.1.1.4. Sales Footprint
20.1.1.5. Strategy Overview
20.1.1.5.1. Marketing Strategy
20.1.2. Thermo Fisher Scientific Inc.
20.1.2.1. Overview
20.1.2.2. Product Portfolio
20.1.2.3. Profitability by Market Segments
20.1.2.4. Sales Footprint
20.1.2.5. Strategy Overview
20.1.2.5.1. Marketing Strategy
20.1.3. Illumina, Inc
20.1.3.1. Overview
20.1.3.2. Product Portfolio
20.1.3.3. Profitability by Market Segments
20.1.3.4. Sales Footprint
20.1.3.5. Strategy Overview
20.1.3.5.1. Marketing Strategy
20.1.4. Danaher
20.1.4.1. Overview
20.1.4.2. Product Portfolio
20.1.4.3. Profitability by Market Segments
20.1.4.4. Sales Footprint
20.1.4.5. Strategy Overview
20.1.4.5.1. Marketing Strategy
20.1.5. PerkinElmer Inc.
20.1.5.1. Overview
20.1.5.2. Product Portfolio
20.1.5.3. Profitability by Market Segments
20.1.5.4. Sales Footprint
20.1.5.5. Strategy Overview
20.1.5.5.1. Marketing Strategy
20.1.6. Shimadzu Corporation
20.1.6.1. Overview
20.1.6.2. Product Portfolio
20.1.6.3. Profitability by Market Segments
20.1.6.4. Sales Footprint
20.1.6.5. Strategy Overview
20.1.6.5.1. Marketing Strategy
20.1.7. Bruker
20.1.7.1. Overview
20.1.7.2. Product Portfolio
20.1.7.3. Profitability by Market Segments
20.1.7.4. Sales Footprint
20.1.7.5. Strategy Overview
20.1.7.5.1. Marketing Strategy
20.1.8. QIAGEN
20.1.8.1. Overview
20.1.8.2. Product Portfolio
20.1.8.3. Profitability by Market Segments
20.1.8.4. Sales Footprint
20.1.8.5. Strategy Overview
20.1.8.5.1. Marketing Strategy
20.1.9. Agilent Technologies, Inc.
20.1.9.1. Overview
20.1.9.2. Product Portfolio
20.1.9.3. Profitability by Market Segments
20.1.9.4. Sales Footprint
20.1.9.5. Strategy Overview
20.1.9.5.1. Marketing Strategy
20.1.10. CYTENA GmbH
20.1.10.1. Overview
20.1.10.2. Product Portfolio
20.1.10.3. Profitability by Market Segments
20.1.10.4. Sales Footprint
20.1.10.5. Strategy Overview
20.1.10.5.1. Marketing Strategy
20.1.11. 10x Genomics
20.1.11.1. Overview
20.1.11.2. Product Portfolio
20.1.11.3. Profitability by Market Segments
20.1.11.4. Sales Footprint
20.1.11.5. Strategy Overview
20.1.11.5.1. Marketing Strategy
21. Assumptions & Acronyms Used22. Research Methodology
